ARTICLE | Clinical News
Olumiant meets Phase III endpoints for atopic dermatitis
February 8, 2019 5:22 AM UTC
Eli Lilly and Co. (NYSE:LLY) and Incyte Corp. (NASDAQ:INCY) said Olumiant baricitinib met the primary endpoints of the Phase III BREEZE-AD1 and BREEZE-AD2 trials to treat moderate to severe atopic dermatitis.
In the double-blind, international studies, Olumiant vs. placebo led to a higher proportion of patients achieving clear or almost clear plaques, as defined by the Investigator's Global Assessment score of atopic dermatitis, at week 16. BREEZE-AD1 and BREEZE-AD2 enrolled about 600 and 750 patients, respectively. ...